Agios Pharmaceuticals

One-line summary: Rare-disease biotech (ticker AGIO); mitapivat accepted for FDA priority review in sickle cell despite missing its co-primary endpoint — the anchor datapoint for the FDA rare-disease right-shift.

What it is

PK-activator/rare-hematology biotech; mitapivat (Pyrukynd) filed for sickle cell disease.

Why it matters to stock-market

The anchor of fda-right-shift-to-rare-disease-refile-rerate: mitapivat was accepted for priority review with no ADCOM despite a missed co-primary VOC endpoint — analysts re-rated AGIO's probability-of-success "well above 50%."

Key facts

• Ticker: AGIO (NASDAQ)

Sources

• 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026

Related

• fda-right-shift-to-rare-disease-refile-rerate
• fda-rare-disease-regulatory-right-shift